Kenvue Inc. (NYSE:KVUE) Receives $25.42 Consensus Price Target from Analysts

Kenvue Inc. (NYSE:KVUE) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $25.42.

KVUE has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target for the company. Royal Bank of Canada decreased their price target on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. UBS Group lifted their price objective on shares of Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 19th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th.

Hedge Funds Weigh In On Kenvue

Several institutional investors and hedge funds have recently added to or reduced their stakes in KVUE. Clearstead Advisors LLC purchased a new position in shares of Kenvue during the third quarter valued at approximately $25,000. Planned Solutions Inc. purchased a new position in shares of Kenvue during the 4th quarter worth $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in shares of Kenvue during the fourth quarter worth $28,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Kenvue in the third quarter valued at $28,000. Finally, AdvisorNet Financial Inc acquired a new position in Kenvue in the third quarter valued at $28,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 0.0 %

Shares of KVUE opened at $21.46 on Monday. Kenvue has a 52 week low of $17.82 and a 52 week high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The business has a 50-day simple moving average of $20.02 and a two-hundred day simple moving average of $20.25.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. As a group, analysts predict that Kenvue will post 1.17 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 dividend on an annualized basis and a yield of 3.73%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.